国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
12期
1674-1675
,共2页
子痫前期%尾加压素Ⅱ%内皮型一氧化氮合酶
子癇前期%尾加壓素Ⅱ%內皮型一氧化氮閤酶
자간전기%미가압소Ⅱ%내피형일양화담합매
Preeclampsia%Urotensin Ⅱ%Endothelial nitric oxide synthase
目的 探讨检测子痫前期孕妇血中尾加压素Ⅱ(UⅡ)与内皮型一氧化氮合酶(eNOS)含量的临床意义.方法 选择我院产科收治的子痫前期孕妇30例(实验组)及普通孕妇30例(对照组),采用ELISA法分别检测2组孕妇血中的尾加压素Ⅱ及内皮型一氧化氮合酶的含量水平值,并对检测结果进行对比分析.结果 实验组尾加压素Ⅱ含量水平值(3.27±1.12) pmol/L明显高于对照组孕妇(1.91±0.39) pmol/L;对照组内皮型一氧化氮合酶含量水平值(89.33±25.79)μmol/L明显低于实验组(125.67±34.36)μmol/L,差异均有统计学意义(P＜0.05).结论 通过检测孕妇血中eNOS与UⅡ水平可反映该病的发展情况,可作为该病的辅助指标,为临床早期监控及治疗提供重要的价值.
目的 探討檢測子癇前期孕婦血中尾加壓素Ⅱ(UⅡ)與內皮型一氧化氮閤酶(eNOS)含量的臨床意義.方法 選擇我院產科收治的子癇前期孕婦30例(實驗組)及普通孕婦30例(對照組),採用ELISA法分彆檢測2組孕婦血中的尾加壓素Ⅱ及內皮型一氧化氮閤酶的含量水平值,併對檢測結果進行對比分析.結果 實驗組尾加壓素Ⅱ含量水平值(3.27±1.12) pmol/L明顯高于對照組孕婦(1.91±0.39) pmol/L;對照組內皮型一氧化氮閤酶含量水平值(89.33±25.79)μmol/L明顯低于實驗組(125.67±34.36)μmol/L,差異均有統計學意義(P＜0.05).結論 通過檢測孕婦血中eNOS與UⅡ水平可反映該病的髮展情況,可作為該病的輔助指標,為臨床早期鑑控及治療提供重要的價值.
목적 탐토검측자간전기잉부혈중미가압소Ⅱ(UⅡ)여내피형일양화담합매(eNOS)함량적림상의의.방법 선택아원산과수치적자간전기잉부30례(실험조)급보통잉부30례(대조조),채용ELISA법분별검측2조잉부혈중적미가압소Ⅱ급내피형일양화담합매적함량수평치,병대검측결과진행대비분석.결과 실험조미가압소Ⅱ함량수평치(3.27±1.12) pmol/L명현고우대조조잉부(1.91±0.39) pmol/L;대조조내피형일양화담합매함량수평치(89.33±25.79)μmol/L명현저우실험조(125.67±34.36)μmol/L,차이균유통계학의의(P＜0.05).결론 통과검측잉부혈중eNOS여UⅡ수평가반영해병적발전정황,가작위해병적보조지표,위림상조기감공급치료제공중요적개치.
Objective To investigate the clinical significance of detecting urotensin Ⅱ (U]Ⅱ) and endothelial nitric oxide synthase (eNOS) in preeclampsia in pregnant women.Methods 30 pregnant women with preeclampsia (experimental group) and 30 normal pregnant women (control group) were selected from our hospital.U Ⅱ and eNOS were detected by ELISA.The detection results were compared and analyzed.Results The levels of U Ⅱ and eNOS were (3.27 ± 1.12) pmol/L and (125.67 ± 34.36) μmol/L in the experimental group and were (1.91 ± 0.39) pmol/L and (89.33 ± 25.79) μ mol/L in the control group,with statistical differences.Conclusions Detecting maternal serum eNOS and U]Ⅱ levels can reflect the development situation of the disease and be used as an auxiliary index of this disease and is valuable for the disease' s early monitoring and treatment.
